Chronic Kidney Diseases Clinical Trial
Official title:
Comparison of the Efficacy of Gabapentin With Loratadine in the Treatment of Uremic Pruritus in Patients of Chronic Kidney Disease
Verified date | March 2023 |
Source | King Edward Medical University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this clinical trial is to compare the efficacy of gabapentin with loratadine in reducing the severity of uremic pruritus in patients of chronic kidney disease and to compare the side effects of both drugs. The main questions it aims to answer are: - Which drug (gabapentin versus loratadine) is more effective in reducing the severity of uremic pruritus? - Which drug (gabapentin versus loratadine) has fewer side effects? Participants were divided into two groups.Group A received loratadine 10mg daily and group B received gabapentin 100mg daily. Both groups were given treatment for 4 weeks. - Participants were asked to grade the severity of pruritus on a numerical rating scale and also answer the Dermatology Life Quality Index Questionnaire (DLQI) - Participants were also asked to report any side effects, if occurred. Researchers compared both groups with regards to improvement in pruritus severity, DLQI score and side effects.
Status | Completed |
Enrollment | 64 |
Est. completion date | October 31, 2022 |
Est. primary completion date | October 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: - Chronic kidney disease, stage 3 and above, irrespective of dialysis status - Persistent pruritus, of moderate to very severe intensity (= 4 points on numerical rating scale), occurring at least 3 times a week, for at least 2 weeks, in a 1-month period. Exclusion Criteria: - Chronic skin conditions such as eczema, psoriasis, etc. - Pruritus due to any other cause, such as metabolic abnormalities, liver disease, etc. - History of drugs causing pruritus such as opioids, etc - Pregnant patients - Preceding history of allergy to either gabapentin or loratadine. |
Country | Name | City | State |
---|---|---|---|
Pakistan | King Edward Medical University/Mayo Hospital | Lahore | Punjab |
Lead Sponsor | Collaborator |
---|---|
King Edward Medical University |
Pakistan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean reduction in pruritus score, from baseline till 4 weeks, as measured on a numerical rating scale. | Reduction in pruritus score as measured on a numerical rating scale, numbered between '0' (corresponding to no itch) and '10' (the worst imaginable itch). | Four weeks | |
Secondary | Mean reduction in Dermatology Life Quality Index Questionnaire score, from baseline till 4 weeks. | Dermatology Life Quality Index Questionnaire score ranging from from 0 (no impairment of life quality) to 30 (maximum impairment). | Four weeks | |
Secondary | Comparison of side effects of gabapentin and loratadine, as reported by the participants. | Four weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06386172 -
Electronic Decision-support System to Improve Detection and Care of Patients With Chronic Kidney Disease in Stockholm
|
N/A | |
Recruiting |
NCT04910867 -
APOL1 Genetic Testing Program for Living Donors
|
N/A | |
Completed |
NCT03434145 -
Changes of Ocular Structures After Hemodialysis in Patients With Chronic Kidney Diseases
|
N/A | |
Recruiting |
NCT04984226 -
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
|
Phase 2 | |
Active, not recruiting |
NCT05887817 -
Effects of Finerenone on Vascular Stiffness and Cardiorenal Biomarkers in T2D and CKD (FIVE-STAR)
|
Phase 4 | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Terminated |
NCT05022329 -
COVID-19 Vaccine Boosters in Patients With CKD
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT04925661 -
HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia
|
Phase 1 | |
Recruiting |
NCT04961164 -
Resistant Starch Prebiotic Effects in Chronic Kidney Disease
|
N/A | |
Completed |
NCT05015647 -
Low Protein Diet in CKD Patients at Risk of Malnutrition
|
N/A | |
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Recruiting |
NCT06094231 -
Treating Patients With Renal Impairment and Altered Glucose MetAbolism With TherapeutIc Carbohydrate Restriction and Sglt2-Inhibiton - a Pilot Study
|
N/A | |
Completed |
NCT04363554 -
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Recruiting |
NCT04831021 -
Pre- or Per-dialytic Physical Exercise : a Cardioprotective Role?
|
N/A | |
Terminated |
NCT04877847 -
Multi-Center Trial Utilizing Low Frequency Ultrasound in the Prevention of Post-Contrast Acute Kidney Injury
|
N/A | |
Recruiting |
NCT04422652 -
Combination of Novel Therapies for CKD Comorbid Depression
|
Phase 2 | |
Completed |
NCT05055362 -
Effect a Honey, Spice-blended Baked Good Has on Salivary Inflammation Markers in Adults: a Pilot Study
|
N/A | |
Not yet recruiting |
NCT06330480 -
Check@Home: General Population Screening for Early Detection of Atrial Fibrillation and Chronic Kidney Disease
|
N/A | |
Recruiting |
NCT03176862 -
Left Ventricular Fibrosis in Chronic Kidney Disease
|
N/A | |
Terminated |
NCT02539680 -
Intestinal Phosphate Transporter Expression in CKD Patients
|
N/A |